Little FDA oversight of Chinese, Indian drugs despite deaths

06/17/2007 | Washington Post, The · NYTimes.com

Cheaper drugs and ingredients from China and India are becoming an increasing part of U.S. sales of generics and over-the-counter drugs without FDA oversight. The agency rarely conducts quality-control inspections in the two countries, even after an ingredient in a Chinese drug caused dozens of deaths in Haiti a decade ago and again recently in Panama.

View Full Article in:

Washington Post, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD